Angiogenesis inhibitor

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

Retrieved on: 
Wednesday, December 13, 2023
Licensing factor, Johns Hopkins University, FGF, HUVEC, Inhibitor, JHU, Itraconazole, Basal-cell carcinoma, Therapy, National Cancer Institute, VDAC1, INTI, Literature, Cell proliferation, Patient, BCC, EGF, Angiogenesis inhibitor, Prostate cancer, Endothelium, AMPK, VEGF, Neoplasm, System, License, Blood, Enzyme inhibitor, Cancer, ATP, Lung cancer, Growth, API, Metastasis, Invention, RNA, Patent, Pharmaceutical industry, Vaccine

TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors". Angiogenesis Inhibitors, as described by the National Cancer Institute, are unique cancer fighting agents as they block the growth of blood vessels that support tumor growth rather than blocking the growth of the tumor cells themselves. Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.

Key Points: 
  • TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors".
  • Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.
  • Inhibitor believes the License is a mutually beneficial agreement, yielding a modest annual royalty rate with milestone payments typical to such a license.
  • A total of 13 new 'surgically eligible' lesions across 8 of the 38 patients developed over the duration of the study.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Biology, Angiology, Medical specialties, Growth factors, Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Vascular endothelial growth factor, Angiogenesis inhibitor, Angiogenesis

WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Key Points: 
  • WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.
  • OncXernas approach pairs those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Clinical medicine, Ophthalmology, Angiology, Vascular endothelial growth factor, Intravitreal administration, Macular degeneration, Angiogenesis, Retina, Angiogenesis inhibitor

The proliferation of abnormal blood vessels in the retina is stimulated by VEGF.

Key Points: 
  • The proliferation of abnormal blood vessels in the retina is stimulated by VEGF.
  • There are on average 200,000 new incidences of wet AMD per year in the United States alone.
  • The prevalence of DME is high, affecting approximately 1.1 million adults in the United States.\n4D-150 is designed as a dual transgene, intravitreal gene therapy inhibiting four distinct VEGF family members to prevent angiogenesis for the treatment of wet AMD and DME.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.\n'

Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

Retrieved on: 
Thursday, May 6, 2021
Angiology, Branches of biology, Medical specialties, Vascular endothelial growth factor, Angiogenesis, Endothelium, Angiogenesis inhibitor, Anti–vascular endothelial growth factor therapy

The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.

Key Points: 
  • The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.
  • Most approved therapeutics target vascular endothelial growth factor (VEGF), a pro-angiogenic factor with neurotrophic and neuroprotective effects.
  • However, approximately 50% of Patients do not respond to anti-VEGF/Corticosteroids therapies.\nOCU200 inhibited cell proliferation, cell invasion and tube formation by endothelial cells.
  • Arun Upadhyay, VP and Head of R&D, Ocugen Inc.\n'

Outlook on the $30 Billion Vascular Endothelial Growth Factor Inhibitor Global Market to 2030 - Identify Growth Segments for Investment

Retrieved on: 
Thursday, April 8, 2021
Branches of biology, Angiology, Medical specialties, Growth factors, Vascular endothelial growth factor, Endothelium, Tyrosine kinase receptors, Angiogenesis inhibitor, VPF

This report provides strategists, marketers and senior management with the critical information they need to assess the global vascular endothelial growth factor (VEGF) inhibitor market.

Key Points: 
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global vascular endothelial growth factor (VEGF) inhibitor market.
  • The vascular endothelial growth factor (VEGF) inhibitor market global report answers all these questions and many more.
  • Market Characteristics - The market characteristics section of the report defines and explains the vascular endothelial growth factor (VEGF) inhibitor market.
  • The top 10 companies in the market occupied 99% of market share in the global vascular endothelial growth factor (VEGF) inhibitor market.

Worldwide Vascular Endothelial Growth Factor Inhibitor Industry to 2030 - Players Include Regeneron Pharmaceuticals, Astrazeneca & Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 6, 2021
Health, Pharmaceutical, Branches of biology, Growth factors, Angiology, Vascular endothelial growth factor, Endothelium, Tyrosine kinase inhibitors, Angiogenesis inhibitor, VPF

Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

Key Points: 
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • The top opportunities in the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type will arise in the tecentriq segment, which will gain $4,596.9 million of global annual sales by 2025.
  • The vascular endothelial growth factor (VEGF) inhibitor market size will gain the most in the USA at $7,015.6 million.

Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 10, 2021
Health, Pharmaceutical, Branches of biology, Growth factors, Angiology, Vascular endothelial growth factor, VEGF receptor, Angiogenesis inhibitor, VEGFR-2 inhibitor

The "Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of vascular endothelial growth factor (VEGF) inhibitor biosimilars.
  • Vascular endothelial growth factor (VEGF)/vascular endothelial growth factor (VEGFR) inhibitors are agents that inhibit VEGF and VEGFR activity.
  • Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer

Retrieved on: 
Wednesday, October 28, 2020
Clinical medicine, Drugs, Medicine, Monoclonal antibodies, Ramucirumab, Breakthrough therapy, Cancer immunotherapy, Orphan drugs, Atezolizumab, Checkpoint inhibitor, Angiogenesis inhibitor, PD-L1

Basilea is the sponsor of the study and Lilly will collaborate on clinical aspects and provide clinical supply of ramucirumab.

Key Points: 
  • Basilea is the sponsor of the study and Lilly will collaborate on clinical aspects and provide clinical supply of ramucirumab.
  • The FIDES-03 study will assess the efficacy and safety of derazantinib as monotherapy and combination therapy with ramucirumab and paclitaxel or with Roches PD-L1 checkpoint inhibitor atezolizumab.
  • Dr. Marc Engelhardt, Chief Medical Officer, said: The agreement with Lilly allows us to investigate the potential of derazantinib combined with ramucirumab and paclitaxel, which is the standard of care in the second-line treatment of gastric cancer.
  • Its unique kinase inhibition profile may complement the anti-angiogenic effects of ramucirumab in the treatment of patients with advanced gastric cancer.

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Retrieved on: 
Monday, October 26, 2020
Branches of biology, Tyrosine kinase receptors, Angiology, Medical specialties, Clusters of differentiation, Growth factors, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Angiogenesis inhibitor, Vascular endothelial growth factor, Angiogenesis

In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).

Key Points: 
  • In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).
  • The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.
  • Dr. Laurenz Kellenberger, Chief Scientific Officer, said: Our development strategy for derazantinib is focused on strengthening the evidence for its differentiation versus other FGFR inhibitors.
  • The preclinical data on derazantinibs anti-angiogenic activity presented at the conference show that it may provide additional activity on top of its established primary anti-tumor effects in FGFR-positive solid tumors.

RIBOMIC Enters License Agreement with AJU Pharma for RBM-007 in Age-related Macular Degeneration

Retrieved on: 
Tuesday, March 17, 2020
Seniors, Clinical trials, Professional services, Small business, Biotechnology, Health, Consumer, Pharmaceutical, Optical, Medicine, Branches of biology, Clinical medicine, Angiology, RTT, Macular degeneration, Senescence, Breakthrough therapy, Angiogenesis inhibitor, Cancer treatments, Vascular endothelial growth factor, Intravitreal administration

Currently approved therapies for wet AMD, intravitreal injections of anti-VEGF drugs, have shown dramatic visual benefits for wet AMD patients.

Key Points: 
  • Currently approved therapies for wet AMD, intravitreal injections of anti-VEGF drugs, have shown dramatic visual benefits for wet AMD patients.
  • The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD.
  • Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe.
  • "RIBOMIC," and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.